VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured €3 million to advance its lead antibody-drug ...

Apr 27, 2026--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that th ...

One of the hotter areas of cancer drug research involves using a particular type of bispecific antibody as the backbone for therapeutic combinations intended to bring a multi-pronged attack to tumors.

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company') announced that the sNDA (the 'Application') for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also ...

The platform will be applied to identify potential biomarkers linked to treatment response prior to upcoming trial phases.

The Japanese pharmaceutical company Taiho Pharmaceutical is set to acquire the Swiss antibody-drug conjugate (ADC) company Araris Biotech for $400 million. Taiho and Araris have been collaborating to ...

The market opportunities in the Antibody Drug Conjugate (ADC) space are centered around the advancement of novel ADCs addressing unmet needs in targeted cancer therapy. Innovations in payloads, ...

TOKYO, JAPAN, February 10, 2026 /EINPresswire.com/ — Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter “Chugai”) and Araris Biotech AG (hereafter ...

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) ...